Summary
Gilead Sciences, Inc. reported total revenues of $7.8 billion for the second quarter of 2016, a 6% decrease year-over-year, primarily driven by a 6% decline in product sales to $7.7 billion. This decrease was largely attributed to lower sales of Hepatitis C (HCV) treatments, particularly Harvoni, which saw a 29% drop in sales for the quarter. Despite the decline in HCV revenue, Gilead demonstrated growth in its HIV franchise, with sales of tenofovir alafenamide (TAF)-based products like Genvoya, Descovy, and Odefsey showing strong uptake. Research and development expenses significantly increased to $1.5 billion due to strategic acquisitions and pipeline progression, while net income attributable to Gilead was $3.5 billion, or $2.58 per diluted share, a decrease from the prior year's $4.5 billion, or $2.92 per diluted share. The company also continued its aggressive share repurchase program, demonstrating a commitment to returning capital to shareholders.
Financial Highlights
58 data points| Revenue | $7.78B |
| Cost of Revenue | $864.00M |
| Gross Profit | $6.79B |
| R&D Expenses | $1.48B |
| SG&A Expenses | $890.00M |
| Operating Expenses | $3.24B |
| Operating Income | $4.54B |
| Interest Expense | $227.00M |
| Net Income | $3.50B |
| EPS (Basic) | $2.62 |
| EPS (Diluted) | $2.58 |
| Shares Outstanding (Basic) | 1.33B |
| Shares Outstanding (Diluted) | 1.35B |
Key Highlights
- 1Total revenues for Q2 2016 were $7.8 billion, a decrease of 6% compared to Q2 2015, primarily due to lower HCV product sales.
- 2Product sales decreased by 6% to $7.7 billion, with HCV product sales (Harvoni, Sovaldi, Epclusa) declining by 7% due to lower sales of Harvoni.
- 3HIV product sales showed strength, increasing by 15% year-over-year for the quarter, driven by TAF-based regimens like Genvoya, Descovy, and Odefsey.
- 4Research and Development (R&D) expenses significantly increased by 81% to $1.5 billion, largely due to acquisitions (Nimbus Apollo) and pipeline progression.
- 5Net income attributable to Gilead was $3.5 billion, down from $4.5 billion in Q2 2015, resulting in diluted EPS of $2.58 compared to $2.92.
- 6Gilead continued significant capital allocation towards share repurchases, spending $9 billion on buybacks in the first half of 2016, including a $5 billion accelerated share repurchase program.
- 7The company received FDA approval for Epclusa (sofosbuvir/velpatasvir), the first pan-genotypic, single-tablet regimen for HCV, and gained European Commission approval for Odefsey (emtricitabine/rilpivirine/tenofovir alafenamide) for HIV treatment.